-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Repare Therapeutics (NASDAQ:RPTX) Now Covered by Analysts at Capital One Financial
Repare Therapeutics (NASDAQ:RPTX) Now Covered by Analysts at Capital One Financial
Capital One Financial initiated coverage on shares of Repare Therapeutics (NASDAQ:RPTX – Get Rating) in a research report report published on Friday morning, Briefing.com reports. The firm issued an overweight rating and a $28.00 price objective on the stock.
Separately, HC Wainwright dropped their price target on shares of Repare Therapeutics from $38.00 to $25.00 and set a buy rating on the stock in a research note on Thursday, November 17th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $30.80.
Get Repare Therapeutics alerts:Repare Therapeutics Trading Down 5.5 %
NASDAQ:RPTX opened at $13.46 on Friday. The firm has a market capitalization of $564.81 million, a price-to-earnings ratio of -18.44 and a beta of 0.11. The firm's fifty day simple moving average is $15.50 and its 200 day simple moving average is $13.94. Repare Therapeutics has a twelve month low of $8.06 and a twelve month high of $18.68.
Repare Therapeutics (NASDAQ:RPTX – Get Rating) last posted its earnings results on Wednesday, November 9th. The company reported $1.71 earnings per share for the quarter, beating the consensus estimate of ($0.20) by $1.91. The business had revenue of $112.55 million for the quarter, compared to analyst estimates of $43.23 million. Repare Therapeutics had a negative net margin of 21.31% and a negative return on equity of 9.53%. On average, analysts predict that Repare Therapeutics will post -0.69 earnings per share for the current year.Insider Buying and Selling
In related news, Director Davis Jerel sold 250,000 shares of Repare Therapeutics stock in a transaction on Friday, December 9th. The shares were sold at an average price of $16.00, for a total transaction of $4,000,000.00. Following the sale, the director now owns 2,094,451 shares of the company's stock, valued at approximately $33,511,216. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 30.30% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Repare Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Bartlett & Co. LLC bought a new stake in shares of Repare Therapeutics in the 2nd quarter worth about $28,000. UBS Group AG increased its position in shares of Repare Therapeutics by 26.3% in the 3rd quarter. UBS Group AG now owns 3,551 shares of the company's stock worth $43,000 after purchasing an additional 739 shares during the last quarter. Bpifrance SA bought a new stake in shares of Repare Therapeutics in the 2nd quarter worth about $113,000. Tower Research Capital LLC TRC bought a new stake in shares of Repare Therapeutics in the 3rd quarter worth about $113,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of Repare Therapeutics in the 3rd quarter worth about $143,000. Institutional investors own 78.19% of the company's stock.
About Repare Therapeutics
(Get Rating)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Featured Articles
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- 3 Airline Stocks Taking Off in 2023
- Why Wall Street Has Bullish Targets on Target Stock
- What Macy's Guidance Means For Retail
- Fortinet Stock Price Bumpy, Here Is Why
- Apexigen Stock Soars After Analyst Rating, Is It Time to Buy?
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Capital One Financial initiated coverage on shares of Repare Therapeutics (NASDAQ:RPTX – Get Rating) in a research report report published on Friday morning, Briefing.com reports. The firm issued an overweight rating and a $28.00 price objective on the stock.
第一資本金融發起的股份覆蓋範圍 反复治療 (納斯達克:RPTX — 獲得評分) 在上週五早上發表的研究報告中，簡報網站報導。該公司對該股發出了超重評級和 28.00 美元的價格目標。
Separately, HC Wainwright dropped their price target on shares of Repare Therapeutics from $38.00 to $25.00 and set a buy rating on the stock in a research note on Thursday, November 17th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $30.80.
另外，韋賴特 HC 溫賴特將 RepARE 治療藥物股票的價格目標價格從 38.00 美元降至 25.00 美元，並於 11 月 17 日（星期四）在研究報告中設定了該股票的買入評級。一位股票研究分析師將該股票評為持有評級，其中五名股票向該股發出買入評級。根據 MarketBeat 的數據，該公司的共識評級為中等買入，共識價格目標為 30.80 美元。
Repare Therapeutics Trading Down 5.5 %
反复治療法交易下降 5.5%
NASDAQ:RPTX opened at $13.46 on Friday. The firm has a market capitalization of $564.81 million, a price-to-earnings ratio of -18.44 and a beta of 0.11. The firm's fifty day simple moving average is $15.50 and its 200 day simple moving average is $13.94. Repare Therapeutics has a twelve month low of $8.06 and a twelve month high of $18.68.
納斯達克：RPTX 上週五以 13.46 美元開盤。該公司的市值為 564.81 億美元，價格與收益比為 -18.44，測試版為 0.11。該公司的五十天簡單移動平均線為 15.50 美元，其 200 日簡單移動平均線為 13.94 美元。反复治療有十二個月低點 8.06 美元和十二個月的高點 18.68 美元。
Insider Buying and Selling
內幕買賣
In related news, Director Davis Jerel sold 250,000 shares of Repare Therapeutics stock in a transaction on Friday, December 9th. The shares were sold at an average price of $16.00, for a total transaction of $4,000,000.00. Following the sale, the director now owns 2,094,451 shares of the company's stock, valued at approximately $33,511,216. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 30.30% of the stock is currently owned by insiders.
在相關消息中，導演戴維斯·傑雷爾在 12 月 9 日（星期五）的一次交易中出售了 25 萬股 Reparel 治療股票。股票以 16 美元的平均價格出售，總交易額為 4,000 萬美元。出售後，董事現擁有該公司股票的 2,094,451 股，價值約為 33,511,216 美元。該交易在與證券交易委員會的法律文件中披露，該文件可通過以下方式訪問 這個鏈接。30.30％ 的股票目前由內部人士擁有。
Institutional Investors Weigh In On Repare Therapeutics
機構投資者對 Repin 治療的權衡
Hedge funds and other institutional investors have recently modified their holdings of the stock. Bartlett & Co. LLC bought a new stake in shares of Repare Therapeutics in the 2nd quarter worth about $28,000. UBS Group AG increased its position in shares of Repare Therapeutics by 26.3% in the 3rd quarter. UBS Group AG now owns 3,551 shares of the company's stock worth $43,000 after purchasing an additional 739 shares during the last quarter. Bpifrance SA bought a new stake in shares of Repare Therapeutics in the 2nd quarter worth about $113,000. Tower Research Capital LLC TRC bought a new stake in shares of Repare Therapeutics in the 3rd quarter worth about $113,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of Repare Therapeutics in the 3rd quarter worth about $143,000. Institutional investors own 78.19% of the company's stock.
對沖基金和其他機構投資者最近修改了股票的持有量。巴特利特 & 有限公司有限責任公司在第二季度購買了 Repis 治療藥物股份的新股份，價值約為 28,000 美元。瑞銀集團股份有限公司在第三季度增加了 26.3% 的瑞寶治療股份地位。瑞銀集團股份公司在上一季度額外購買 739 股股票後，現擁有該公司股票價值 43,000 美元的 3,551 股。Bpifrance SA 在第二季度購買了價值約 113,000 美元的雷波治療藥物股份的新股份。塔研究資本有限責任公司 TRC 在第三季度購買了 Repis 治療的股份的新股份，價值約為 113,000 美元。最後，福克斯運行管理有限責任公司在第三季度購買了價值約 143,000 美元的 Repel 治療藥物股份的新股份。機構投資者擁有公司股票的 78.19%。
About Repare Therapeutics
關於瑞普雷療法
(Get Rating)
(取得評分)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Repare Therapetics Inc 是一家臨床階段的精密腫瘤學公司，通過在加拿大和美國使用其合成致死性方法來發現並開發治療藥物。該公司使用其 SniprX，這是一個專有的，全基因組且支持 CRISPR 的平台，系統地發現和開發高度針對性的癌症療法，該療法專注於基因組不穩定性，包括 DNA 損傷修復。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- 3 Airline Stocks Taking Off in 2023
- Why Wall Street Has Bullish Targets on Target Stock
- What Macy's Guidance Means For Retail
- Fortinet Stock Price Bumpy, Here Is Why
- Apexigen Stock Soars After Analyst Rating, Is It Time to Buy?
- 獲取有關雷帕爾治療研究報告（RPTX）的免費副本
- 3 家航空公司股票在 2023 年起飛
- 為什麼華爾街對目標股票有看漲目標
- 梅西百貨指南對零售意味著什麼
- Fortinet 股價顛簸，這就是為什麼
- APEXIGEN 股票在分析師評級後飆升，是時候買入了嗎？
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Repel 治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收 RepARE 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧